SCHEMBL14474188

SCHEMBL14474188

CNc1nc(-c2ccccn2)nc2c(OC)cc(-c3cc(F)cc(F)c3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 2/20 0.47
▸ ABCG2 Q9UNQ0 2/20 0.47
▸ GRM5 P41594 3/20 0.43
▸ METAP2 P50579 1/20 0.43
▸ METAP1 P53582 1/20 0.43
▸ TRPM8 Q7Z2W7 7/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ LMNA P02545 3/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ MITF O75030 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474182 0.94 ABCB1 (0.47) ABCB1ABCG2GRM5METAP2METAP1
SCHEMBL16185130 0.93 ABCG2 (0.45) ABCB1ABCG2GRM5METAP2METAP1
SCHEMBL16185164 0.90 GRM5 (0.43) ABCB1ABCG2GRM5METAP2METAP1
SCHEMBL14474185 0.88 CYP1A2 (0.38) ABCG2SMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL16185123 0.88 LMNA (0.46) ABCB1ABCG2GRM5METAP2METAP1
SCHEMBL16185151 0.87 L3MBTL1 (0.45) ABCB1ABCG2GRM5METAP2METAP1
SCHEMBL14474671 0.87 L3MBTL1 (0.47) ABCB1ABCG2GRM5METAP2METAP1
SCHEMBL16185161 0.86 SCN9A (0.39) ABCB1ABCG2GRM5SMN1; SMN2LMNA
SCHEMBL16185162 0.86 SCN9A (0.40) ABCB1ABCG2SMN1; SMN2LMNAALDH1A1
SCHEMBL14474187 0.85 SCN9A (0.38) ABCB1ABCG2GRM5SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
WO-2013003586-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB ABCB1 3803/4885ABCG2 1597/4885GRM5 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback